Analysis done by the American Cancer Society Cancer Action Network (ACS CAN) in six states, reports that coverage transparency has improved since 2015 but it is still hard for consumers to determine prescription drug coverage and cost-sharing information in Affordable Care Act (ACA) marketplace plans. The report found that patient cost-sharing is high, and coverage limits – particularly prior authorization and quantity limits – remain prevalent for commonly used cancer drugs. Read the full report by ACS CAN here.
Last Updated on May 12, 2020 by Aimed Alliance
